Silk Road Medical - SILK Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SILK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SILK, but not buy additional shares or sell existing shares.
View SILK analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price objectives for Silk Road Medical's shares. Their SILK share price forecasts range from $38.00 to $60.00. On average, they predict the company's share price to reach $47.00 in the next twelve months. This suggests that the stock has a possible downside of 11.7%.
View analysts price targets for SILK or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $42.61 at the start of the year. Since then, SILK stock has increased by 25.0% and is now trading at $53.25.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our SILK earnings forecast.

Silk Road Medical, Inc (NASDAQ:SILK) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09. The firm earned $24.70 million during the quarter, compared to the consensus estimate of $26.03 million. Silk Road Medical had a negative net margin of 45.16% and a negative trailing twelve-month return on equity of 86.73%. During the same quarter in the prior year, the company earned ($0.31) earnings per share.

Silk Road Medical updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $134.00 million-$137.00 million, compared to the consensus revenue estimate of $130.60 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (8.76%), Vanguard Group Inc. (8.38%), Kayne Anderson Rudnick Investment Management LLC (3.69%), State Street Corp (2.14%), Jennison Associates LLC (1.95%) and Ensign Peak Advisors Inc (1.68%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, Lucas W Buchanan, Pincus & Co Warburg and Richard Ruedy.
View institutional ownership trends.

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SILK stock can currently be purchased for approximately $53.25.

Silk Road Medical (NASDAQ:SILK) has a market capitalization of $2.03 billion and generates $101.47 million in revenue each year. The company earns $-49,810,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

The company employs 352 workers across the globe.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The official website for the company is www.silkroadmed.com. The company can be reached via phone at (408) 720-9002, via email at investors@silkroadmed.com, or via fax at 408-720-9013.